Entries tagged "Biogen Idec Inc."

You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "Biogen Idec Inc.."

12 result(s) displayed (1 - 12 of 12)

Stage set for showdown over Elan

Eyes are on Royal Pharma as it weighs its best and final offer. Continue reading

Posted on April 19, 2013 9:05 AM

Royalty Pharma makes $6.5B unsolicited bid for Elan

The pharmaceuticals investor discloses its bid plan after hitting a roadblock in talks with the Irish drugmaker. Continue reading

Posted on February 25, 2013 8:48 AM

Elan outlines how it will use Tysabri sale proceeds

The Irish drugmaker will take the opportunity after the $3.25 billion sale of the multiple sclerosis treatment to make acquisitions, buy shares and refinance its debt. Continue reading

Posted on February 22, 2013 4:27 PM

Biogen buys out Tysabri rights for $3.3B

Elan cedes control of the blockbuster multiple sclerosis drug, its sole revenue producer, in an attempt to pursue a new strategic direction through acquisitions. Continue reading

Posted on February 6, 2013 11:23 AM

Bayer, Evotec to develop endometriosis therapies

The two German companies will collaborate on the development of three compounds for the female health malady over a five-year period under a deal that could be worth as much as $750 million. Continue reading

Posted on October 1, 2012 4:04 PM

After drug's collapse, all eyes on Elan

The pharmaceutical company's share price is buoyed by takeover speculation after its Alzheimer's compound fails a clinical trial Continue reading

Posted on August 8, 2012 9:08 AM

Biogen buys Stromedix

The deal for the fibrosis drugmaker could top $562 million Continue reading

Posted on February 14, 2012 3:22 PM

FDA issues key generic-drug guidelines

The draft outlines the approval process for biosimilars Continue reading

Posted on February 13, 2012 9:16 AM

Biotech milestones, blockbusters and orphans

In 2011, risk sharing returned to dealmaking in the sector as overconfidence left the market. Continue reading

Posted on December 9, 2011 12:00 PM

Teva buys out Japanese JV partner

The generic drugmaker will pay Kowa $150 million as part of a plan to establish itself as a market leader in Japan. Continue reading

Posted on September 26, 2011 3:13 PM

Survivor, biotech

For every Genentech or Amgen, there's a host of research-based companies that have struggled to get by. Here's the story of how three biotechs kept themselves going when times got tough. Continue reading

Posted on April 25, 2011 12:45 PM

Therapeutic investing

Why companies developing cancer treatments are particularly attractive right now. Continue reading

Posted on September 22, 2009 1:46 PM

Movable Type search results powered by Fast Search